摘要
目的:观察呋喃唑酮抗幽门螺杆菌治疗的疗效。方法:抽选2017年1月—12月期间在本院接受抗幽门螺杆菌治疗的76例消化性溃疡患者作为研究对象,并按随机数字表法将其平均分为实验组(A组)与对照组(B、C、D组),各19例,实验组使用的治疗药物为泮托拉唑+阿莫西林+枸橼酸铋钾+呋喃唑酮进行联合治疗,对照组中B组:泮托拉唑+阿莫西林+枸橼酸铋钾+左氧氟沙星;C组:泮托拉唑+阿莫西林+枸橼酸铋钾+克拉霉素;D组:泮托拉唑+阿莫西林+枸橼酸铋钾+甲硝唑。比较两组的治疗效果。结果:对照组的总有效率、幽门螺杆菌根除率略低于实验组,不良反应略高于实验组,差异均不存在统计学意义(P>0.05)。结论:呋喃唑酮在抗幽门螺杆菌治疗中具有极高的使用价值,疗效理想。
Objective： To observe the efficacy of furazolidone in the treatment of Helicobacter pylori. Methods： 38 patients with peptic ulcer treated with anti-Helicobacter pylori in our hospital from January to December 2017, were selected as study subjects, and randomly divided into observation group and control group with 19 cases each. The observation group was treated with Losseck amoxicillin furazolidone and the control group with conventional therapy. The therapeutic effects were compared between the two groups. Results： The total effective rate and the eradication rate of Helicobacter pylori in the control group were slightly lower than those in the observation group, and the adverse reactions were slightly higher than those in the observation group. The difference was not statistically significant （P〉0.05）. Conclusion： Furazolidone has a high value in the treatment of Helicobacter pylori and has an ideal curative effect. It is worth popularizing in the clinical treatment of various primary hospitals.
作者
鄢小华
林文英
YAN Xiao-hua;LIN Wen-ying(Department of internal medicine,Fenyi People＇s Hospital,Fenyi Jiangxi 336600,China)
出处
《药品评价》
CAS
2018年第22期36-37,64,共3页
Drug Evaluation
基金
江西省科学技术厅社会发展领域
编号:2014BBG70047
